Articles tagged "Co-stimulation"

2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
Anti- CD154 / CD40 Costimulation Blockade is Superior to Tacrolimus in Prolonging Survival in Pig-to-Nonhuman Primate Renal Xenotransplantation
B. P. Lovasik¹, A. J. Matar¹, C. Breeden¹, J. Jenkins², J. Tector³, S. C. Kim¹, A. B. Adams¹
¹Emory Transplant Center, Emory University, Atlanta, GA, ²Yerkes National Primate Center, Emory University, Atlanta, GA, ³University of Alabama at Birmingham, Birmingham, AL
*Purpose: Costimulation blockade strategies targeting the CD40/CD154 pathway are highly effective in preventing xenograft rejection in pig-to-nonhuman primate (NHP) transplantation models. The aim of this…
2019 American Transplant Congress
Implementation of a De Novo Belatacept Protocol
D. Wojciechowski¹, M. Jacobs², K. Safa¹, H. Gilligan¹, H. Eliot¹, W. W. Williams, Jr¹
¹Massachusetts General Hospital, Boston, MA, ²Wake Forest, Winston-Salem, NC
*Purpose: The use of belatacept with basiliximab induction and maintenance MMF/prednisone when compared to cyclosporine is associated with superior long-term patient and graft survival but…
2019 American Transplant Congress
Expansion of Regulatory T and B Cells in Swine Rendered Tolerant of Allogeneic Vascularized Composite Allografts via Mixed Chimerism
G. Saviane¹, A. Lellouch¹, A. Andrews¹, L. Lantieri², M. Randolph¹, G. Benichou¹, C. Cetrulo Jr¹
¹Center for Transplantation Sciences, Division of Plastic Surgery, Boston, MA, USA, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²European Georges Pompidou Hospital, University of Paris, Department of Plastic Surgery, Paris, France
*Purpose: Prevention of acute rejection of vascularized composite allografts (VCAs) requires ongoing systemic immunosuppression, which subject patients to infectious, metabolic, reno-vascular and neoplastic complications. It…
2019 American Transplant Congress
Early Conversion to Belatacept in High Risk Renal Transplant Recipients
A. Santeusanio, A. Bhansali, R. Shapiro, V. Delaney, S. Florman, G. De Boccardo
Mount Sinai Hospital, New York, NY
*Purpose: This study describes our experience with early conversion to belatacept therapy in a diverse patient population including patients with donor specific antibodies (DSA). The…
2019 American Transplant Congress
Belatacept Monotherapy in Kidney Transplant Recipients with Failed Allografts Reduces Humoral Sensitization in a Single Center Randomized Controlled Trial
I. R. Badell, R. Elbein, R. A. Bray, H. M. Gebel, A. B. Adams, C. P. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: Kidney transplant recipients with failed allografts suffer from high rates of humoral sensitization. Immunosuppression (IS) strategies are highly variable in these patients with many…
2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…
2019 American Transplant Congress
Four-Year Follow Up of Kidney Transplantation Using Alemtuzumab Induction and Belatacept/Sirolimus Maintenance Therapy
A. Kirk¹, H. Xu¹, A. Ghali², A. Mehta², A. Guasch²
¹Surgery, Duke University, Durham, NC, ²Transplant Center, Emory University, Atlanta, GA
*Purpose: Kidney transplantation remains limited by the chronic toxicities associated with calcineurin inhibitors (CNIs) and steroids. The objective of this clinical trial was to determine…
2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
I. R. Badell, P. Vasanth, A. B. Farris, J. M. Robertson, G. M. Karadkhele, C. P. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…
2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
D. Kumar¹, M. Raynaud², P. Halloran³, A. Loupy², J. Chang³, J. Reeve³, I. Yakubu¹, S. Bobba¹, L. Kamal¹, M. Levy¹, C. Bhati¹, P. Kimball¹, A. King¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²Paris Transplant Group, Paris, France, ³Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
*Purpose: Chronic active antibody mediated rejection (cABMR) is a major cause of long-term kidney transplant (KT) loss. Current therapies have unclear efficacy and significant side…